|
|
Line 1: |
Line 1: |
| <small>'''''Synonyms / Brand Names: Cefalessina, Cefalexin Sodium, Cefalexina, Cefalexine, Cefalexinum, Cephalexin 1-hydrate, Cephalexin hydrate, Cephalexin monohydrate, Cephalexinum, Cephalexine, CEX,Alcephin, Alexin, Alsporin, Biocef, Carnosporin, Cefa-iskia, Cefablan, Cefadal, Cefadin, Cefadina, Cefaleksin, Cefalin, Cefaloto, Cefaseptin, Cefax, Ceforal, Cefovit, Celexin, Cepastar, Cepexin, Cephacillin, Cephanasten, Cephaxin, Cephin, Cepol, Ceporex, Ceporex Forte, Ceporexin, Ceporexin-E, Ceporexine, Check, Cophalexin, Durantel, Durantel DS, Ed A-Ceph, Erocetin, Factagard, Felexin, Fexin, Ibilex, Ibrexin, Inphalex, Kefalospes, Keflet, Keflex, Kefolan, Keforal, Keftab, Kekrinal, Kidolex, L-Keflex, Lafarine, Larixin, Lenocef, Lexibiotico, Lonflex, Lopilexin, Madlexin, Mamalexin, Mamlexin, Medoxine, Neokef, Neolexina, Novolexin, Nufex, Oracef, Oriphex, Oroxin, Ortisporina, Ospexin, Palitrex, Panixine Disperdose, Pectril, Pyassan, Roceph, Sanaxin, Sartosona, Sencephalin, Sepexin, Servispor, Sialexin, Sinthecillin, Sporicef, Sporidex, Syncl, Syncle, Synecl, Tepaxin, Tokiolexin, Uphalexin, Voxxim, Winlex, Zozarine
| | __NOTOC__ |
| ''''' </small>
| | {{Cephalexin}} |
| | {{CMG}};{{AE}}{{AK}} |
|
| |
|
| {{CMG}}
| | ==Overview== |
| | Cephalexin (INN) or more commonly cephalexin /ˌsɛfəˈlɛksɨn/ is a first-generation cephalosporin antibiotic introduced in 1967 by Eli Lilly and Company.[2][3] It is an orally administered agent with a similar antimicrobial spectrum to the intravenous agents [[cefalotin]] and [[cefazolin]]. It was first marketed as Keflex (Lilly), and is marketed under several other trade names. |
|
| |
|
| ==Dosing and Administration== | | ==Category== |
| '''Adults'''<br>
| | Cephalosporins, first generation. |
| The adult dosage ranges from 1 to 4 g daily in divided doses. The usual adult dose is 250 mg every 6 hours. For the following infections, a dosage of 500 mg may be administered every 12 hours: streptococcal pharyngitis, skin and skin structure infections, and uncomplicated cystitis in patients over 15 years of age. Cystitis therapy should be continued for 7 to 14 days. For more severe infections or those caused by less susceptible organisms, larger doses may be needed. If daily doses of Keflex greater than 4 g are required, parenteral cephalosporins, in appropriate doses, should be considered.
| |
| <br>
| |
| <br>
| |
| '''Pediatric Patients''' <br>
| |
| The usual recommended daily dosage for pediatric patients is 25 to 50 mg/kg in divided doses. For streptococcal pharyngitis in patients over 1 year of age and for skin and skin structure infections, the total daily dose may be divided and administered every 12 hours.
| |
| <br>
| |
| <br>
| |
| ''For more information on dosing please refer to'' [[Cephalexin instructions for administration|Instructions for administration]]
| |
| <br>
| |
| ----
| |
| <br>
| |
| <font size="4">
| |
| [[{{PAGENAME}}#FDA Package Insert Resources|FDA Package Insert Resources]]
| |
| <br></font size><small>Indications, Contraindications, Side Effects, Drug Interactions, etc.</small><font size="4"><br>
| |
| <br>
| |
| [http://www.pace-med-apps.com/gfrcalc.htm Calculate Creatine Clearance]
| |
| <br></font size><small>On line calculator of your patients Cr Cl by a variety of formulas.</small><font size="4"><br>
| |
| <br>
| |
| [http://home.earthlink.net/~sensei11/convert.htm Convert pounds to Kilograms]
| |
| <br></font size><small>On line calculator of your patients weight in pounds to Kg for dosing estimates.</small><font size="4"><br>
| |
| <br> [[{{PAGENAME}}#Publication Resources|Publication Resources]]
| |
| <br></font size><small>Recent articles, WikiDoc State of the Art Review, Textbook Information</small><font size="4"><br>
| |
| <br>
| |
| [[{{PAGENAME}}#Trial Resources|Trial Resources]]
| |
| <br></font size><small>Ongoing Trials, Trial Results</small><font size="4"><br>
| |
| <br>
| |
| [[{{PAGENAME}}#Guidelines & Evidence Based Medicine Resources|Guidelines & Evidence Based Medicine Resources]]
| |
| <br></font size><small>US National Guidelines, Cochrane Collaboration, etc.</small><font size="4"><br>
| |
| <br>
| |
| [[{{PAGENAME}}#Media Resources|Media Resources]]
| |
| <br></font size><small>Slides, Video, Images, MP3, Podcasts, etc.</small><font size="4"><br><br>
| |
| [[{{PAGENAME}}#Patient Resources|Patient Resources]]
| |
| <br></font size><small>Discussion Groups, Handouts, Blogs, News, etc.</small><font size="4"><br>
| |
| <br>
| |
| [[{{PAGENAME}}#International Resources|International Resources]]
| |
| <br></font size><small>en Español</small><font size="4"><br>
| |
| <br>
| |
| ----
| |
| <br>
| |
| <br>
| |
| <br>
| |
| <br>
| |
|
| |
|
| ==FDA Package Insert Resources== | | ==US Brand Names== |
| [[{{PAGENAME}} indications|Indications]]
| | CEPHALEXIN<sup>®</sup>,KEFLEX<sup>®</sup> |
| <br>
| |
| <br>
| |
| [[{{PAGENAME}} contraindications|Contraindications]]
| |
| <br> | |
| <br> | |
| [[{{PAGENAME}} side effects|Side Effects]]
| |
| <br>
| |
| <br>
| |
| [[{{PAGENAME}} drug interactions|Drug Interactions]]
| |
| <br>
| |
| <br>
| |
| [[{{PAGENAME}} precautions|Precautions]]
| |
| <br>
| |
| <br>
| |
| [[{{PAGENAME}} overdose|Overdose]]
| |
| <br>
| |
| <br>
| |
| [[{{PAGENAME}} instructions for administration|Instructions for Administration]]
| |
| <br>
| |
| <br>
| |
| [[{{PAGENAME}} how supplied|How Supplied]]
| |
| <br>
| |
| <br>
| |
| [http://google2.fda.gov/search?q=cache:PNdbxe478sYJ:www.fda.gov/medwatch/SAFETY/2004/nov_PI/Keflex_PI.doc+Cephalexin&access=p&output=xml_no_dtd&ie=UTF-8&lr=&client=FDA&proxystylesheet=FDA&oe=UTF-8 FDA label]
| |
| <br>
| |
| <br>
| |
| [http://google2.fda.gov/search?q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&x=0&y=0&client=FDA&site=FDA&lr=&proxystylesheet=FDA&output=xml_no_dtd&getfields=* FDA on {{PAGENAME}}]
| |
| <br>
| |
| <br>
| |
| </font size><small>[[{{PAGENAME}}#Dosing and Administration|Return to top]]</small><font size="4">
| |
| <br>
| |
| <br>
| |
|
| |
|
| ==Publication Resources== | | ==Dosing and Administration== |
| [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=search&db=pubmed&term={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}} Most Recent Articles on {{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}]
| | Cephalexin tablets, capsules and oral suspension are administered orally. |
| <br>
| |
| <br>
| |
| [http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&db=pubmed&term={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}%20AND%20systematic%5Bsb%5D Review Articles on {{PAGENAME}}]
| |
| <br>
| |
| <br>
| |
| [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&db=pubmed&term={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}+AND+%28%28N+Engl+J+Med%5Bta%5D%29+OR+%28Lancet%5Bta%5D%29+OR+%28BMJ%5Bta%5D%29%29 Articles on {{PAGENAME}} in N Eng J Med, Lancet, BMJ]
| |
| <br>
| |
| <br>
| |
| [[WikiDoc state of the art review on {{PAGENAME}}|WikiDoc State of the Art Review]]
| |
| <br>
| |
| <br>
| |
| [http://books.google.com/books?ie=UTF-8&oe=utf-8&q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&qt_s=Search&sa=N&tab=gp Textbook Information on {{PAGENAME}}]
| |
| <br>
| |
| <br>
| |
| </font size><small>[[{{PAGENAME}}#Dosing and Administration|Return to top]]</small><font size="4">
| |
| <br>
| |
| <br>
| |
| | |
| ==Trial Resources==
| |
| [http://clinicaltrials.gov/search/open/condition={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}} Ongoing Trials with {{PAGENAME}} at Clinical Trials.gov]
| |
| <br>
| |
| <br>
| |
| [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&db=pubmed&term={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}+AND+%28randomized+controlled+trial%5BPublication+Type%5D+OR+%28randomized%5BTitle%2FAbstract%5D+AND+controlled%5BTitle%2FAbstract%5D+AND+trial%5BTitle%2FAbstract%5D%29%29 Trial Results with {{PAGENAME}}]
| |
| <br>
| |
| <br>
| |
| </font size><small>[[{{PAGENAME}}#Dosing and Administration|Return to top]]</small><font size="4">
| |
| <br>
| |
| <br>
| |
|
| |
|
| ==Guidelines & Evidence Based Medicine Resources== | | ==FDA Package Insert== |
| [http://www.guideline.gov/search/searchresults.aspx?Type=3&txtSearch={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&num=20 US National Guidelines Clearinghouse on {{PAGENAME}}] | | ''' [[Cephalexin description|Description]]''' |
| <br>
| | '''| [[Cephalexin clinical pharmacology|Clinical Pharmacology]]''' |
| <br>
| | '''| [[Cephalexin microbiology|Microbiology]]''' |
| [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&db=pubmed&term={{urlencode:({{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}) AND (Cochrane Database Syst Rev[ta])}} Cochrane Collaboration on {{PAGENAME}}] | | '''| [[Cephalexin indications and usage|Indications and Usage]]''' |
| <br>
| | '''| [[Cephalexin contraindications|Contraindications]]''' |
| <br>
| | '''| [[Cephalexin warnings and precautions|Warnings and Precautions]]''' |
| [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&db=pubmed&term={{urlencode:({{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}) AND (Cost effectiveness)}} Cost Effectiveness of {{PAGENAME}}] | | '''| [[Cephalexin adverse reactions|Adverse Reactions]]''' |
| <br>
| | '''| [[Cephalexin overdosage|Overdosage]]''' |
| <br>
| | '''| [[Cephalexin clinical studies|Clinical Studies]]''' |
| </font size><small>[[{{PAGENAME}}#Dosing and Administration|Return to top]]</small><font size="4">
| | '''| [[Cephalexin dosage and administration|Dosage and Administration]]''' |
| <br>
| | '''| [[Cephalexin how supplied|How Supplied]]''' |
| <br>
| | '''| [[Cephalexin labels and packages|Labels and Packages]]''' |
| ==Media Resources==
| |
| [http://www.google.com/search?q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}+ppt&ie=utf-8&oe=utf-8&aq=t&rls=org.mozilla:en-US:official&client=firefox-a Powerpoint Slides on {{PAGENAME}}] | |
| <br>
| |
| <br>
| |
| [http://images.google.com/images?q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&ie=UTF-8&oe=utf-8&rls=org.mozilla:en-US:official&client=firefox-a&um=1&sa=N&tab=wi Images of {{PAGENAME}}] | |
| <br>
| |
| <br>
| |
| [http://www.google.com/search?hl=en&client=firefox-a&rls=org.mozilla%3Aen-US%3Aofficial&hs=hPo&q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}+podcasts+OR+MP3&btnG=Search Podcasts & MP3s on {{PAGENAME}}] | |
| <br>
| |
| <br>
| |
| [http://video.google.com/videosearch?q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&ie=UTF-8&oe=utf-8&rls=org.mozilla:en-US:official&um=1&sa=N&tab=fv# Videos on {{PAGENAME}}] | |
| <br>
| |
| <br>
| |
| </font size><small>[[{{PAGENAME}}#Dosing and Administration|Return to top]]</small><font size="4">
| |
| <br>
| |
| <br>
| |
|
| |
|
| ==Patient Resources==
| |
| [[{{PAGENAME}} (patient information)|Patient Information from National Library of Medicine]]
| |
| <br>
| |
| <br>
| |
| [http://www.google.com/search?hl=en&q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}+more:for_patients&cx=disease_for_patients&sa=N&oi=cooptsr&resnum=0&ct=col3&cd=1 Patient Resources on {{PAGENAME}}]
| |
| <br>
| |
| <br>
| |
| [http://groups.google.com/groups/search?ie=UTF-8&oe=utf-8&q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&qt_s=Search Discussion Groups on {{PAGENAME}}]
| |
| <br>
| |
| <br>
| |
| [http://www.google.com/search?hl=en&client=firefox-a&rls=org.mozilla:en-US:official&q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}+more:patient_handouts&cx=disease_for_health_professionals&sa=N&oi=coopctx&resnum=0&ct=col1&cd=3 Patient Handouts on {{PAGENAME}}]
| |
| <br>
| |
| <br>
| |
| [http://blogsearch.google.com/blogsearch?q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&ie=UTF-8&oe=utf-8&rls=org.mozilla:en-US:official&client=firefox-a&um=1&sa=N&tab=wb Blogs on {{PAGENAME}}]
| |
| <br>
| |
| <br>
| |
| [http://news.google.com/news?q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&ie=UTF-8&oe=utf-8&rls=org.mozilla:en-US:official&client=firefox-a&um=1&sa=N&tab=wn {{PAGENAME}} in the News]
| |
| <br>
| |
| <br>
| |
| [http://finance.google.com/finance?ie=UTF-8&oe=utf-8&q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&qt_s=Search&sa=N&tab=te {{PAGENAME}} in the Marketplace]
| |
| <br>
| |
| <br>
| |
| </font size><small>[[{{PAGENAME}}#Dosing and Administration|Return to top]]</small><font size="4">
| |
| <br>
| |
| <br>
| |
|
| |
|
| ==International Resources==
| |
| [http://www.google.com/search?q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}+en+espanol&ie=utf-8&oe=utf-8&aq=t&rls=org.mozilla:en-US:official&client=firefox-a {{PAGENAME}} en Español]
| |
| <br>
| |
| <br>
| |
| </font size><small>[[{{PAGENAME}}#Dosing and Administration|Return to top]]</small><font size="4">
| |
| <br>
| |
| <br>
| |
| </font size>
| |
| ----
| |
| {{FDA}}
| |
|
| |
|
| [[Category:Drugs]] | | ==References== |
| | {{Reflist|2}} |
| | http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/050405s097lbl.pdf |
| | [[Category:Antibiotics]] |
| | [[Category:Wikinfect]] |